Discover and read the best of Twitter Threads about #cme
Most recents (24)
@TumorBoardTues 1/17 #TumorBoardTuesday #RenalCancer #OncTwitter
68yo👨🏾
HTN
T2DM
Arthritis
✂️2022: L Radical Nephrectomy
🔬Clear cell #RenalCellCarcinoma
📏8.2 cm, Grade 2, extends into renal vein (T3a)
❓No lymph nodes sampled (NX)
❌No other dz sites
What would you pick for adj therapy?
68yo👨🏾
HTN
T2DM
Arthritis
✂️2022: L Radical Nephrectomy
🔬Clear cell #RenalCellCarcinoma
📏8.2 cm, Grade 2, extends into renal vein (T3a)
❓No lymph nodes sampled (NX)
❌No other dz sites
What would you pick for adj therapy?
@TumorBoardTues 2/17 #TumorBoardTuesday #RCC
🚨There’s significant relapse risk in ≥ Stage II RCC even after local tx✂️
🔢We use tools like Fox Chase’s ASSURE Prognostic nomogram to estimate disease free survival (DFS)
📈Example for our pt below
📚Correa, Andres F cancernomograms.com/nomograms/492
🚨There’s significant relapse risk in ≥ Stage II RCC even after local tx✂️
🔢We use tools like Fox Chase’s ASSURE Prognostic nomogram to estimate disease free survival (DFS)
📈Example for our pt below
📚Correa, Andres F cancernomograms.com/nomograms/492
@TumorBoardTues 3/17 #TumorBoardTuesday @brian_rini
⭐RCC Adjuvant Therapy⭐
⚖️Weighing recurrence risk with a long list 📜 of adj trial results?
💉Focusing on adju IO & review:
✨KEYNOTE-564: Pembro
✨CheckMate 914: Nivo/Ipi
✨IMmotion010: Atezo
✨PROSPER: Periop Nivo
⭐RCC Adjuvant Therapy⭐
⚖️Weighing recurrence risk with a long list 📜 of adj trial results?
💉Focusing on adju IO & review:
✨KEYNOTE-564: Pembro
✨CheckMate 914: Nivo/Ipi
✨IMmotion010: Atezo
✨PROSPER: Periop Nivo
1/26 #TumorBoardTuesday #LungCancer #OncTwitter @DrSteveMartin
⛹🏻♀️Case 1⛹️♂️
80 yo 👵🏼 never 🚬
🩻 Imaging shows R lung mass
🦴 New hip pain found to have R femoral lytic lesion
⚒️Undergoes ORIF R femur
🔬R femur path: metastatic squamous cell carcinoma, TPS 1%
🤔What next?
⛹🏻♀️Case 1⛹️♂️
80 yo 👵🏼 never 🚬
🩻 Imaging shows R lung mass
🦴 New hip pain found to have R femoral lytic lesion
⚒️Undergoes ORIF R femur
🔬R femur path: metastatic squamous cell carcinoma, TPS 1%
🤔What next?
2/26 #TumorBoardTuesday #LCSM
🩸🧬Surprise, surprise - you send ctDNA!
➡️Results show MET Exon 14 skipping mutation (VAF 0.5%)
👵🏼started on MET TKI capmatinib 400mg BID
👍CTCAP 2 months later shows impressive response 🙌🏽
🩸🧬Surprise, surprise - you send ctDNA!
➡️Results show MET Exon 14 skipping mutation (VAF 0.5%)
👵🏼started on MET TKI capmatinib 400mg BID
👍CTCAP 2 months later shows impressive response 🙌🏽
3/26 #TumorBoardTuesday #LCSM
👨🏻🏫Mini tweetorial 1👩🏻🏫
⭐️~10.5% of pts w SCC have actionable alterations
🕵🏻♀️Consider NGS in nonadeno #NSCLC pts who
1⃣🚭or light 🚬hx (1-10 pack yrs)
2⃣young age (dx age <50)
bc potentially ⬆️ prevalence driver muts
📚@IASLC jto.org/article/S1556-…
👨🏻🏫Mini tweetorial 1👩🏻🏫
⭐️~10.5% of pts w SCC have actionable alterations
🕵🏻♀️Consider NGS in nonadeno #NSCLC pts who
1⃣🚭or light 🚬hx (1-10 pack yrs)
2⃣young age (dx age <50)
bc potentially ⬆️ prevalence driver muts
📚@IASLC jto.org/article/S1556-…
@TumorBoardTues @drsarahsam 1/24 #TumorBoardTuesday #BreastCancer #OncTwitter
54yo 👩🏻 post-menopausal
HTN
hypothyroidism
FH: aunt with late-onset BC
Germline genetic testing: negative
🔪Dec ‘10 Left lumpectomy + SLNB:
left IDC G2
ER 95%
PgR 10%
HER2-neg (IHC 1+)
Ki67 35%
stage pT2 (25 mm) pN0
Oncotype 32
54yo 👩🏻 post-menopausal
HTN
hypothyroidism
FH: aunt with late-onset BC
Germline genetic testing: negative
🔪Dec ‘10 Left lumpectomy + SLNB:
left IDC G2
ER 95%
PgR 10%
HER2-neg (IHC 1+)
Ki67 35%
stage pT2 (25 mm) pN0
Oncotype 32
@TumorBoardTues @drsarahsam 2/24 #TumorBoardTuesday #BCSM
☢️Jan ‘11: TC x 4 ➡️ XRT
Treatment well tolerated, apart from alopecia, G2 fatigue
Summer ‘11 – started letrozole
🔀 Fall ‘11 – switch to exemestane due to G3 arthralgias ➡️ improvement of symptoms
2016 completed 5 years of Aromatase Inhibitor
☢️Jan ‘11: TC x 4 ➡️ XRT
Treatment well tolerated, apart from alopecia, G2 fatigue
Summer ‘11 – started letrozole
🔀 Fall ‘11 – switch to exemestane due to G3 arthralgias ➡️ improvement of symptoms
2016 completed 5 years of Aromatase Inhibitor
@TumorBoardTues @drsarahsam 3/24 #TumorBoardTuesday #BCSM
Apr ‘21 – Mild abdo discomfort
🩻CT CAP scan:
liver: 5 lesions, max 15 mm
bone: spine & ribs
enlarged mediastinal lymph nodes
🩸: G1 anemia, normal LFTs, no other abnormality
🔬US-guided liver biopsy:
IDC, grade 2, ER 90%, PR 0%, HER2-0, Ki67 25%
Apr ‘21 – Mild abdo discomfort
🩻CT CAP scan:
liver: 5 lesions, max 15 mm
bone: spine & ribs
enlarged mediastinal lymph nodes
🩸: G1 anemia, normal LFTs, no other abnormality
🔬US-guided liver biopsy:
IDC, grade 2, ER 90%, PR 0%, HER2-0, Ki67 25%
When a #solarflare or filament eruption occurs, we don't immediately know if it launched a #CoronalMassEjection #CME
Great article from #SpaceWeatherLive
answers the question:
How do we know if a CME happened, if it's Earth directed & when it's going to arrive?
#spaceweather
Great article from #SpaceWeatherLive
answers the question:
How do we know if a CME happened, if it's Earth directed & when it's going to arrive?
#spaceweather
Here are 4 methods...
1. Using the proton flux monitor
1. Using the proton flux monitor
2. Using SOHO/LASCO coronagraph imagery
1) Welcome to a new #accredited #tweetorial, "Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC," featuring the highlights of a symposium presented at the #ESMOIO22 congress.
@myESMO #LCSM #FOAMed
@myESMO #LCSM #FOAMed
2) The faculty for this outstanding program were @peters_solange (Chair) 🇨🇭, @HosseinBorghaei 🇺🇸, Natasha Leighl MD 🇨🇦, and @dplanchard 🇫🇷. A truly international roster of experts in #oncology!
Don't miss prior accredited courses in this space at oncologytweetorials-ce.com/category/lung-….
Don't miss prior accredited courses in this space at oncologytweetorials-ce.com/category/lung-….
3) This program is supported by an educational grant from Sanofi. Statement of accreditation and author disclosures are at oncologytweetorials-ce.com/disclosures/.
1) Welcome to this #accredited #tweetorial on genetic testing in the evaluation of patients with cystic kidney disease. #Kidney #cysts are a frequent finding, ranging from simple cysts to suspected or confirmed #ADPKD.
Expert author @dguerrot of @CHURouen 🇫🇷 leads us!
Expert author @dguerrot of @CHURouen 🇫🇷 leads us!
2) This program is supported by an educational grant from Otsuka Pharmaceuticals & is intended for #HCPs. #Physicians #Physicianassociates #nurses #nursepractioners #pharmacists 🇺🇸🇨🇦🇪🇺🇬🇧 earn CE/#CME credit. Statement of accreditation & faculty disclosures ckd-ce.com/disclosures
3a) Fortuitous discovery of non-malignant kidney cysts is increasingly frequent with age, and often leads to #nephrology referral.
@TumorBoardTues @TomJayram @arnabguonc @UroCancerMD @vinay_onc @simon_p_kim @AlexAlvaro_PSC @AlyaShamsan @MichaelStaehler @DrOmarMian @kaydaustin @josiegarcia1 @LeeJonesMBA @mcricardoa @UroDocAsh @Uromigos @AJangMD @BenMironMD @ChrisSweens1 @Tanjin097 @NikiTripathi27 1/15 #TumorBoardTuesday #BladderCancer #OncTwitter
71 y/o 👨🏽🦳
Former 🚬
👨🏭Worked in various factories in 80s-00s
Recently diagnosed metastatic #UrothelialCancer (lymph nodes/lung)
🤨 What would you pick for your first line of therapy?
71 y/o 👨🏽🦳
Former 🚬
👨🏭Worked in various factories in 80s-00s
Recently diagnosed metastatic #UrothelialCancer (lymph nodes/lung)
🤨 What would you pick for your first line of therapy?
@TumorBoardTues @TomJayram @arnabguonc @UroCancerMD @vinay_onc @simon_p_kim @AlexAlvaro_PSC @AlyaShamsan @MichaelStaehler @DrOmarMian @kaydaustin @josiegarcia1 @LeeJonesMBA @mcricardoa @UroDocAsh @Uromigos @AJangMD @BenMironMD @ChrisSweens1 @Tanjin097 @NikiTripathi27 2/15 #TumorBoardTuesday
1L treatment for UC
📍cis eligible: SOC is gem/cis
📚pubmed.ncbi.nlm.nih.gov/11001674/
📍Frontline EV+P promising early phase results in cis-ineligible
📚ascopubs.org/doi/abs/10.120…
📍Ongoing ph3 trial: EV+pembro vs gem/cis (or carbo) clinicaltrials.gov/ct2/show/NCT04…
1L treatment for UC
📍cis eligible: SOC is gem/cis
📚pubmed.ncbi.nlm.nih.gov/11001674/
📍Frontline EV+P promising early phase results in cis-ineligible
📚ascopubs.org/doi/abs/10.120…
📍Ongoing ph3 trial: EV+pembro vs gem/cis (or carbo) clinicaltrials.gov/ct2/show/NCT04…
@TumorBoardTues @TomJayram @arnabguonc @UroCancerMD @vinay_onc @simon_p_kim @AlexAlvaro_PSC @AlyaShamsan @MichaelStaehler @DrOmarMian @kaydaustin @josiegarcia1 @LeeJonesMBA @mcricardoa @UroDocAsh @Uromigos @AJangMD @BenMironMD @ChrisSweens1 @Tanjin097 @NikiTripathi27 @PGrivasMDPhD @PauloBergerot @spsutkaMD @shilpaonc @montypal @tompowles1 @NazliDizman 3/15 #TumorBoardTuesday
Checkpoint☑️
✅Pembrolizumab: approved as single agent for those NOT eligible for platinum chemotherapy
📚thelancet.com/journals/lanon…
BUT
✨KEYNOTE-361: adding pembro to platinum based chemo did NOT result in PFS/OS improvement
📚thelancet.com/journals/lanon…
Checkpoint☑️
✅Pembrolizumab: approved as single agent for those NOT eligible for platinum chemotherapy
📚thelancet.com/journals/lanon…
BUT
✨KEYNOTE-361: adding pembro to platinum based chemo did NOT result in PFS/OS improvement
📚thelancet.com/journals/lanon…
🔥Crohn’s Perianal Fistula - #MondayNightIBD w all🌟faculty 🔥 CME 👉 bit.ly/CPF2 🔸Supported by an edu grant from @TakedaPharma 🔸 twitter.com/i/broadcasts/1…
2/#MondayNightIBD #Crohns #PerianalFistula #MedTwitter #GITwitter
✅Answer #IBDPolls👇
🗓 Mark your calendar - Live Q&A @ 8p ET/5p PT
📲Tweet your❓to be addressed Monday!
📸 Faculty disclosures & important CME info👇
✅Answer #IBDPolls👇
🗓 Mark your calendar - Live Q&A @ 8p ET/5p PT
📲Tweet your❓to be addressed Monday!
📸 Faculty disclosures & important CME info👇
3/#MondayNightIBD #GITwitter #MedTwitter
#Crohns #PerianalFistula #CPF
@BonumCe
👇Answer Pre-Polls before watching 👇
#Crohns #PerianalFistula #CPF
@BonumCe
👇Answer Pre-Polls before watching 👇
📣#GITwitter
Join⚕️@DCharabaty @AmyLightnerMD #DrMarlaDubinsky+ Brandon Pomish 4 #Crohns #PerianalFistula
🗓️#CPF #MNIBDWebinar Sat 2/11
🎯MultiD Mgmt
🎯Stem Cell Therapy
🎯#PatientExperience
🆓#CME👉bit.ly/CPF-MNIBD-CME
🗳️#IBDPolls👇
🔸Supported by an edu grant @TakedaPharma
Join⚕️@DCharabaty @AmyLightnerMD #DrMarlaDubinsky+ Brandon Pomish 4 #Crohns #PerianalFistula
🗓️#CPF #MNIBDWebinar Sat 2/11
🎯MultiD Mgmt
🎯Stem Cell Therapy
🎯#PatientExperience
🆓#CME👉bit.ly/CPF-MNIBD-CME
🗳️#IBDPolls👇
🔸Supported by an edu grant @TakedaPharma
1/#PreConvo #IBDPoll #Crohns #PerianalFistula
#MNIBDWebinar #CPF
🆓#CME🔗bit.ly/CPF-MNIBD-CME
🟢Where are you in your career?
#MNIBDWebinar #CPF
🆓#CME🔗bit.ly/CPF-MNIBD-CME
🟢Where are you in your career?
2/#PreConvo #IBDPoll 1️⃣
#MNIBDWebinar #Crohns #PerianalFistula #CPF
🆓#CME🔗bit.ly/CPF-MNIBD-Pre2
🟢The addition of which of the following to an anti-TNF agent is associated with a higher rate of #Crohns #PerianalFistula CPF healing vs the anti-TNF agent alone?
#MNIBDWebinar #Crohns #PerianalFistula #CPF
🆓#CME🔗bit.ly/CPF-MNIBD-Pre2
🟢The addition of which of the following to an anti-TNF agent is associated with a higher rate of #Crohns #PerianalFistula CPF healing vs the anti-TNF agent alone?
1/22 #TumorBoardTuesday #OncTwitter
60yo 👩🏻
ER+/PR-/HER2 low met #BreastCancer
Since 2016: 3 lines of endocrine therapy including AI+CDK 4/6 inhibitor ➡️ Fulvestrant ➡️ Everolimus+exemestane
No actionable mutation
🤨 What would be your first chemotherapy choice:
60yo 👩🏻
ER+/PR-/HER2 low met #BreastCancer
Since 2016: 3 lines of endocrine therapy including AI+CDK 4/6 inhibitor ➡️ Fulvestrant ➡️ Everolimus+exemestane
No actionable mutation
🤨 What would be your first chemotherapy choice:
2/22 #TumorBoardTuesday @MPishvaian @JohnEbbenMDPhD #BreastCancer #BCSM
2021*: Started on capecitabine for 8 months until POD
2022: Switched to paclitaxel for 5 months ➡️ POD in the liver and pleura
🤨 What would be your next step?
2021*: Started on capecitabine for 8 months until POD
2022: Switched to paclitaxel for 5 months ➡️ POD in the liver and pleura
🤨 What would be your next step?
3/22 #TumorBoardTuesday
👩🏻🏫Mini tweetorial 1
📌What is HER2-low?
🔸Traditionally HER2-positive and HER2-negative were separate entities
🔸NOW, HER2-low is a separate entity 👉🏽 1+ or 2+ on IHC and ISH negative‼️
📚@PTarantinoMD @curijoey @stolaney1 aacrjournals.org/cancerdiscover…
👩🏻🏫Mini tweetorial 1
📌What is HER2-low?
🔸Traditionally HER2-positive and HER2-negative were separate entities
🔸NOW, HER2-low is a separate entity 👉🏽 1+ or 2+ on IHC and ISH negative‼️
📚@PTarantinoMD @curijoey @stolaney1 aacrjournals.org/cancerdiscover…
📣#GITwitter #PedsGI
⚕️Join experts @valcohranmd @Subramanian1MD ⚕️& @DCharabaty addressing the long & the short of:
🎯Optimizing care of #ShortBowelSyndrome
🏆🆓 #CME 🔗bit.ly/3wLGPzF
Supported by an edu grant @TakedaPharma
⚕️Join experts @valcohranmd @Subramanian1MD ⚕️& @DCharabaty addressing the long & the short of:
🎯Optimizing care of #ShortBowelSyndrome
🏆🆓 #CME 🔗bit.ly/3wLGPzF
Supported by an edu grant @TakedaPharma
2/#MondayNightIBD #GITwitter #PedsGI #MedEd #MedTwitter #MNIBDWebinar #BonumCE
Earn 🆓 #CME 🎫
ℹ️ 🔗 bit.ly/3wLGPzF
📸 Faculty disclosures & important CME info 👇
Earn 🆓 #CME 🎫
ℹ️ 🔗 bit.ly/3wLGPzF
📸 Faculty disclosures & important CME info 👇
3/#MondayNightIBD #GITwitter #PedsGI #MedEd #MedTwitter #MNIBDWebinar #BonumCE
🟠Full CME ℹ️ 🔗bit.ly/3wLGPzF
🟠Make sure you answer the pre-polls! 👉 bit.ly/3JOd7BU
🔴 Where are you in your career?
🟠Full CME ℹ️ 🔗bit.ly/3wLGPzF
🟠Make sure you answer the pre-polls! 👉 bit.ly/3JOd7BU
🔴 Where are you in your career?
👋#PedsGI #GITwitter
🗓️Feb 6-Join @Subramanian1MD @valcohranmd @DCharabaty
🔦#ShortBowelSyndrome
⬆️⬇️ Safety & efficacy of med tx
🔑4 your practice
🆓#CME👉bit.ly/3wLGPzF
Support by an edu grant from @TakedaPharma
🗳️#PreConvo #IBDPolls👇
🟢Where are u in ur career?
🗓️Feb 6-Join @Subramanian1MD @valcohranmd @DCharabaty
🔦#ShortBowelSyndrome
⬆️⬇️ Safety & efficacy of med tx
🔑4 your practice
🆓#CME👉bit.ly/3wLGPzF
Support by an edu grant from @TakedaPharma
🗳️#PreConvo #IBDPolls👇
🟢Where are u in ur career?
#PreConvo #IBDPoll 1️⃣
🆓#CME🔗bit.ly/3kN8m0Y
🟢The GLP-2 analog teduglutide was shown in clinical studies to be associated w/ which of the following outcomes?
🆓#CME🔗bit.ly/3kN8m0Y
🟢The GLP-2 analog teduglutide was shown in clinical studies to be associated w/ which of the following outcomes?
#PreConvo #IBDPoll 2️⃣
🆓#CME🔗bit.ly/3kN8m0Y
🟢Young adult pt w/ SBS is experiencing significant diarrhea (≥20 BM/day) despite tx w 8 mg/day loperamide.
Appropriate mgmt includes _____
🆓#CME🔗bit.ly/3kN8m0Y
🟢Young adult pt w/ SBS is experiencing significant diarrhea (≥20 BM/day) despite tx w 8 mg/day loperamide.
Appropriate mgmt includes _____
🔔Set your⏰
🗓TODAY, Mon 30 Jan @ 🇺🇸 2-2:30p ET/11a PT
🇪🇺7p GMT/8p CEST
⭐️Best of #IBD from #UEGWeek
👉🙋🏻LIVE Q&A w @Iris_Dotan @CharlieMuz @MRegueiroMD & @DCharabaty
📲Tweet your❓b4 & during the session
🗒Abstracts discussed📸👇
#CME ℹ️bit.ly/3XgqsH8
#ICYMI 🎥🔗👇
🗓TODAY, Mon 30 Jan @ 🇺🇸 2-2:30p ET/11a PT
🇪🇺7p GMT/8p CEST
⭐️Best of #IBD from #UEGWeek
👉🙋🏻LIVE Q&A w @Iris_Dotan @CharlieMuz @MRegueiroMD & @DCharabaty
📲Tweet your❓b4 & during the session
🗒Abstracts discussed📸👇
#CME ℹ️bit.ly/3XgqsH8
#ICYMI 🎥🔗👇
🙌 @my_ueg X #MondayNightIBD 🙌◦◦◦◦◦◦◦◦◦◦◦◦🎯 Best of #UEGWeek ◦◦◦◦ CME🔗bit.ly/MNIBD-UEG2022 ◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦◦ Support by edu grants from @abbvie & BMS twitter.com/i/broadcasts/1…
2/#MondayNightIBD #UEGWeek
🆓#CME🔗bit.ly/3XgqsH8
📲Tweet your❓for Mon LIVE Q&A @ 2p ET/ 7p GMT/ 8p CEST
📍Where are you in your career?
🆓#CME🔗bit.ly/3XgqsH8
📲Tweet your❓for Mon LIVE Q&A @ 2p ET/ 7p GMT/ 8p CEST
📍Where are you in your career?
3/ #MondayNightIBD X #UEGWeek 2022 Best in #IBD
✨Faculty @Iris_Dotan, @CharlieMuz, @MRegueiroMD, & @DCharabaty ✨
🤝 In collab w/ @my_ueg, @BonumCe
🆓#CME🔗bit.ly/3XgqsH8
📲Tweet you questions👇🏽to be answered LIVE by the experts Monday Jan 30 2pmET/ 7pmGMT/ 8pmCEST
✨Faculty @Iris_Dotan, @CharlieMuz, @MRegueiroMD, & @DCharabaty ✨
🤝 In collab w/ @my_ueg, @BonumCe
🆓#CME🔗bit.ly/3XgqsH8
📲Tweet you questions👇🏽to be answered LIVE by the experts Monday Jan 30 2pmET/ 7pmGMT/ 8pmCEST
1) Welcome to a new #accredited #tweetorial on #Bronchiectasis (#NCFB or #bronchiectasis) & its management, by Christina Thornton MD (@Cthornton32), respirologist & clinician scientist in Calgary 🇨🇦. Follow along and earn 0.75h CE/#CME #physicians #nurses #NPs #PAs #pharmacists!
2) I am very excited to be among the founding faculty in this initiative! FOLLOW US for awesome expert-led education #pulmtwitter!
👍@BronchiectasisR @COPDFoundation @EMBARCnetwork @ELF @profJDchalmers @sunjayMD @DrHollyKeir @becleartoday @ephesians_1_7 @NTMinfo @AlibertiStefano
👍@BronchiectasisR @COPDFoundation @EMBARCnetwork @ELF @profJDchalmers @sunjayMD @DrHollyKeir @becleartoday @ephesians_1_7 @NTMinfo @AlibertiStefano
3) This program is supported by an educational grant from Insmed & is intended for healthcare professionals. Statement of accreditation and faculty disclosures at pulmonarymed-ce.com/disclosures/. CE/#CME credit from @academiccme.
@MondayNightIBD @DCharabaty @BonumCe @TakedaPharma 2/ #MondayNightIBD #ShortBowelSyndrome #MedTwitter #GITwitter #MedPeds @BonumCe
🟠Earn #CME 🏆on Twitter!
🟠Full CME ℹ️ 🔗bit.ly/3Hgnpcf
📸 Faculty disclosures & important CME info 👇
🟠Earn #CME 🏆on Twitter!
🟠Full CME ℹ️ 🔗bit.ly/3Hgnpcf
📸 Faculty disclosures & important CME info 👇
@MondayNightIBD @DCharabaty @BonumCe @TakedaPharma 3/#MondayNightIBD
💊💉Meds = important 🛠 in mgmt of #ShortBowelSyndrome
💎Antimotility & antisecretory agents frequently used to control stool loss
💎Incl loperamide, diphenoxylate w atropine, codeine, & tincture of opium
💎Most effective ~30 min B4 meals & @ bedtime 🛏
💊💉Meds = important 🛠 in mgmt of #ShortBowelSyndrome
💎Antimotility & antisecretory agents frequently used to control stool loss
💎Incl loperamide, diphenoxylate w atropine, codeine, & tincture of opium
💎Most effective ~30 min B4 meals & @ bedtime 🛏
@MondayNightIBD @DCharabaty @BonumCe @TakedaPharma 4/Growth factors also available for #ShortBowelSyndrome
🚦Somatropin (rhGH) approved in SBS
🛑Use largely discontinued due to unacceptable toxicity & modest long-term efficacy
#MondayNightIBD
🚦Somatropin (rhGH) approved in SBS
🛑Use largely discontinued due to unacceptable toxicity & modest long-term efficacy
#MondayNightIBD
#BTC #CME
分析一波数据：
CME持仓：本周CME经销商持仓变化不大，经纪商多头继续明显加仓，空头明显减仓，换算多头增加7000个BTC；与之相反的是大户的持仓变化，大户空头明显加仓，多头略微加仓，换算空头增加5500个BTC；经纪商和大户有着相反的操作方向，接下来我们看一下总仓位的变化情况
分析一波数据：
CME持仓：本周CME经销商持仓变化不大，经纪商多头继续明显加仓，空头明显减仓，换算多头增加7000个BTC；与之相反的是大户的持仓变化，大户空头明显加仓，多头略微加仓，换算空头增加5500个BTC；经纪商和大户有着相反的操作方向，接下来我们看一下总仓位的变化情况
CME总体仓位本周继续增加，有增量资金进场的信号，存量资金并未大量止盈离场，我们可以看到CME的仓位在北京时间1月20号的下午4点也就是价格在208-211时新增了2600个BTC仓位，在站稳22之后，又新增了近4000个BTC仓位，通过周报可以看到这些仓位的变化主要是由经纪商的多头和大户的空头建仓增加所致
我们再来看一下币安和okex的仓位变化情况，币安和okex这前两大所的持仓量为啥一直提不上去，通过usd和btc的两种持仓量来看，很多人的仓位在拉升中明显下降(空头止损或者爆仓，多头止盈)，usd为单位的总持仓虽然缓慢上升，但这是由于btc价格上涨导致的持仓量被动上涨，这和cme的持仓变化是截然不同的
💥#EndometrialCancer TKI/IO safety data & AE mgmt webinar 💥┈┈┈ w @DrMMurphy & @drteplinsky ┈┈┈🔹#CME info 👉 bit.ly/3Vqtabi 👈 @BonumCE ┈┈┈🔸Supported by edu grants from Eisai & @Merck 🔹#TumorBoardTuesday #gyncsm #OncTwitter twitter.com/i/broadcasts/1…
1/#TumorBoardTuesday #OncTwitter
#1:Answer #PreTest❓bit.ly/PreTest-AEs-EC
#2:Tell us who u are👇
#3:🔁Retweet & tag colleagues
🧧#CME ℹ️bit.ly/3Vqtabi
Supported by edu grants from Eisai & @Merck
🟢Where r u in your career?
#1:Answer #PreTest❓bit.ly/PreTest-AEs-EC
#2:Tell us who u are👇
#3:🔁Retweet & tag colleagues
🧧#CME ℹ️bit.ly/3Vqtabi
Supported by edu grants from Eisai & @Merck
🟢Where r u in your career?
2/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc #EndometrialCancer
🟠Earn 🆓 #CME 🏆
🟠#CME ℹ️🔗bit.ly/3YRDkog
📸 Faculty disclosures & important CME info 👇
🟠Earn 🆓 #CME 🏆
🟠#CME ℹ️🔗bit.ly/3YRDkog
📸 Faculty disclosures & important CME info 👇
💥#EndometrialCancer TKI/IO safety data & AE mgmt webinar 💥┈┈┈ w @DrMMurphy & @drteplinsky ┈┈┈🔹#CME info 👉 bit.ly/3Vqtabi 👈 @BonumCE ┈┈┈🔸Supported by edu grants from Eisai & @Merck 🔹#TumorBoardTuesday #gyncsm #OncTwitter twitter.com/i/broadcasts/1…
1/#TumorBoardTuesday #OncTwitter
#1:Answer #PreTest❓🔗bit.ly/EC_AEs_TBTpre
#2:Tell us who u are👇
#3:🔁Retweet & tag colleagues
🧧#CME ℹ️bit.ly/3Vqtabi
Supported by edu grants from Eisai & @Merck
🟢Where r u in your career?
#1:Answer #PreTest❓🔗bit.ly/EC_AEs_TBTpre
#2:Tell us who u are👇
#3:🔁Retweet & tag colleagues
🧧#CME ℹ️bit.ly/3Vqtabi
Supported by edu grants from Eisai & @Merck
🟢Where r u in your career?
3/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc #EndometrialCancer
🟠Earn 🆓 #CME 🏆
🟠#CME ℹ️🔗bit.ly/3YRDkog
📸 Faculty disclosures & important CME info 👇
🟠Earn 🆓 #CME 🏆
🟠#CME ℹ️🔗bit.ly/3YRDkog
📸 Faculty disclosures & important CME info 👇
1/#TumorBoardTuesday #OncTwitter
🗓️TODAY🗓 w @DrTeplinsky & @TumorBoardTues
🎥#EndometrialCancer - Mnging TKI/IO AEs
#CMEℹ️ bit.ly/3Vqtabi
Support by edu grants from Eisai & @Merck
🚨Be ready @ 8p ET/5p PT
✅Answer #PreTest👇
🔁RT & tag 🩺
🟢Where r u in your career?
🗓️TODAY🗓 w @DrTeplinsky & @TumorBoardTues
🎥#EndometrialCancer - Mnging TKI/IO AEs
#CMEℹ️ bit.ly/3Vqtabi
Support by edu grants from Eisai & @Merck
🚨Be ready @ 8p ET/5p PT
✅Answer #PreTest👇
🔁RT & tag 🩺
🟢Where r u in your career?
2/#TumorBoardTuesday #OncTwitter #GynCSM #gynonc
#CME🔗bit.ly/3YRDkog
🟢#PreTest Q 1️⃣
📊Diarrhea, nausea, & vomiting are common GI toxicities associated w pembro + lenvatinib combo therapy.
🟢Which other tox may occur if these GI toxicities are not effectively managed?
#CME🔗bit.ly/3YRDkog
🟢#PreTest Q 1️⃣
📊Diarrhea, nausea, & vomiting are common GI toxicities associated w pembro + lenvatinib combo therapy.
🟢Which other tox may occur if these GI toxicities are not effectively managed?
3/#TumorBoardTuesday #GynCSM #EndometrialCancer
#CME 🔗bit.ly/3YRDkog
🟢#PreTest Q 2️⃣
📊During tx w pembro + lenvatinib, pt develops grade 3 diarrhea
🛑Lenva held
💊Loperamide Rx
Grade 3 diarrhea persists
🟢Which is the appropriate next step for this pt?
#CME 🔗bit.ly/3YRDkog
🟢#PreTest Q 2️⃣
📊During tx w pembro + lenvatinib, pt develops grade 3 diarrhea
🛑Lenva held
💊Loperamide Rx
Grade 3 diarrhea persists
🟢Which is the appropriate next step for this pt?
1/#TumorBoardTuesday #OncTwitter
🗓️TODAY🗓 w @DrMMurphy & @DrTeplinsky
🎥#EndometrialCancer - Mnging TKI/IO AEs
#CMEℹ️ bit.ly/3Vqtabi
Support by edu grants from Eisai & @Merck
🚨Be ready @ 8p ET/5p PT
✅Answer #PreTest👇
🔁RT & tag 🩺
🟢Where r u in your career?
🗓️TODAY🗓 w @DrMMurphy & @DrTeplinsky
🎥#EndometrialCancer - Mnging TKI/IO AEs
#CMEℹ️ bit.ly/3Vqtabi
Support by edu grants from Eisai & @Merck
🚨Be ready @ 8p ET/5p PT
✅Answer #PreTest👇
🔁RT & tag 🩺
🟢Where r u in your career?
2/#TumorBoardTuesday #OncTwitter #GynCSM #gynonc
#CME🔗bit.ly/3YRDkog
🟢#PreTest Q 1️⃣
📊Diarrhea, nausea, & vomiting are common GI toxicities associated w pembro + lenvatinib combo therapy
🟢Which other tox may occur if these GI toxicities are not effectively managed?
#CME🔗bit.ly/3YRDkog
🟢#PreTest Q 1️⃣
📊Diarrhea, nausea, & vomiting are common GI toxicities associated w pembro + lenvatinib combo therapy
🟢Which other tox may occur if these GI toxicities are not effectively managed?
3/#TumorBoardTuesday #GynCSM #EndometrialCancer
#CME🔗bit.ly/3YRDkog
🟢#PreTest Q 2️⃣
📊During tx w pembro + lenvatinib, pt develops grade 3 diarrhea
🛑Lenva held
💊Loperamide Rx
Grade3️⃣diarrhea persists
🟢What is the next step for this pt?
(cs=corticosteroid)
#CME🔗bit.ly/3YRDkog
🟢#PreTest Q 2️⃣
📊During tx w pembro + lenvatinib, pt develops grade 3 diarrhea
🛑Lenva held
💊Loperamide Rx
Grade3️⃣diarrhea persists
🟢What is the next step for this pt?
(cs=corticosteroid)
1/#OncTwitter #TumorBoardTuesday #MedTweetorial 🧵
✅#EndometrialCancer AE deep dive🤿
🧪Trial results
🔬Tox for TKI-ICI
w @DrMMurphy @MeganLeigh127 & us!
🆓#CME @BonumCe🔗bit.ly/3VBGJEJ
Supported by edu grants from Eisai & @Merck
🟢What's your specialty?
✅#EndometrialCancer AE deep dive🤿
🧪Trial results
🔬Tox for TKI-ICI
w @DrMMurphy @MeganLeigh127 & us!
🆓#CME @BonumCe🔗bit.ly/3VBGJEJ
Supported by edu grants from Eisai & @Merck
🟢What's your specialty?
2/#TumorBoardTuesday #BonumCE #OncTwitter #gyncsm #gynonc #EndometrialCancer #MedTweetorial
🆓 CME > full info➕ref list🗒️& program archive
👉bit.ly/3VBGJEJ
🔑#CME info👇
🆓 CME > full info➕ref list🗒️& program archive
👉bit.ly/3VBGJEJ
🔑#CME info👇
3/#TumorBoardTuesday #BonumCE #OncTwitter #GynOnc #gyncsm #EndometrialCancer
🟢Which I/O +🎯tx combo is FDA approved for treatment of advanced or metastatic #EndometrialCarcinoma?
nivo = nivolumab
dostarlimab = dostarlimab-gxly
pembro = pembrolizumab
🟢Which I/O +🎯tx combo is FDA approved for treatment of advanced or metastatic #EndometrialCarcinoma?
nivo = nivolumab
dostarlimab = dostarlimab-gxly
pembro = pembrolizumab
1a) Welcome to a new #accredited #tweetorial, “MOA and Clinical Trial Data for Novel & Emerging Therapeutic Strategies for #HCM: Can We Target Our Therapy?"
1b) Our expert (and returning @cardiomet_ce) author is Giuseppe Galati MD, MMSc in Heart Failure, FHFA, @GiuseppeGalati_ , Consultant #Cardiologist #HeartFailure & #Cardiomyopathies
2) @GiuseppeGalati_ is in Milan 🇮🇹 This program is intended for #healthcare professionals & is accredited for 0.75h CE/#CME credit for #physicians #physicianassistants #nurses #nursepractitioners #pharmacists.
@TumorBoardTues @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD 1/19 #TumorBoardTuesday #BladderCancer #OncTwitter
74 yo🧓🏼
HTN
DM2
2020: localized Rt upper tract urothelial carcinoma
2020: ✂️ radical nephroureterectomy
🧪Germline testing negative
Complicated by CKD stage 4 after ✂️ (creatinine clearance 25 ml/min)
🩻Restaging CT CAP 1 year
74 yo🧓🏼
HTN
DM2
2020: localized Rt upper tract urothelial carcinoma
2020: ✂️ radical nephroureterectomy
🧪Germline testing negative
Complicated by CKD stage 4 after ✂️ (creatinine clearance 25 ml/min)
🩻Restaging CT CAP 1 year
@TumorBoardTues @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD 🩻 NEW metastatic disease to spine, 🫁 and retroperitoneal lymph nodes
ECOG PS 2
🔬Biopsy of RP lymph node: Metastatic #UrothelialCarcinoma
🧪Molecular: FGFR3-TACC3 fusion, MTAP loss, CDKN2A loss
🤨 What 1L treatment would you pick for this patient?
ECOG PS 2
🔬Biopsy of RP lymph node: Metastatic #UrothelialCarcinoma
🧪Molecular: FGFR3-TACC3 fusion, MTAP loss, CDKN2A loss
🤨 What 1L treatment would you pick for this patient?
@TumorBoardTues @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD 3/19 #TumorBoardTuesday @PGrivasMDPhD @MPishvaian @JohnEbbenMDPhD #UrothelialCancer
🤔 Is the above 74yo 🧓🏼 patient a good candidate for platinum-based chemotherapy?
🤨 Poll: Which of these criteria would make this patient platinum-ineligible?
🤔 Is the above 74yo 🧓🏼 patient a good candidate for platinum-based chemotherapy?
🤨 Poll: Which of these criteria would make this patient platinum-ineligible?
